A Jak2-selective inhibitor potently reverses the immune suppression by modulating the tumor microenvironment for cancer immunotherapy

Biochemical Pharmacology

Volumn 145, Issue , 2017, Pages 132-146

  He, Wei ^a   Zhu, Yi ^b   Mu, Ruoyu ^a   Xu, Jinzhi ^a   Zhang, Xiaoyi ^c   Wang, Chunming ^d   Li, Qiu ^d   Huang, Zhen ^a   Zhang, Junfeng ^a   Pan, Yi ^b   Han, Jianlin ^b   Dong, Lei ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c EMORY UNIVERSITY   (United States)

^d University of Macau   (Macao)

Author keywords

Jak2 STAT3 pathway; Regulatory T cells; Tumor associated macrophages; Tumor immunotherapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOKETONE; ANTINEOPLASTIC AGENT; FLUORINATED BETA AMINO KETONE; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; CYTOKINE; JAK2 PROTEIN, HUMAN; KETONE; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG SCREENING; EX VIVO STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; THP-1 CELL LINE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR MODEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL LINE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; MACROPHAGE; METABOLISM; NEOPLASM;

ANIMALS; BINDING SITES; CELL LINE; CELL SURVIVAL; CYTOKINES; HUMANS; JANUS KINASE 2; KETONES; MACROPHAGES; MACROPHAGES, PERITONEAL; MICE; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN BINDING; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 85028735613     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.08.019     Document Type: Article

References (45)

1. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348:6230 (2015), 56–61.
2. Anguille, S., Smits, E.L., Lion, E., van Tendeloo, V.F., Berneman, Z.N., Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 15:7 (2014), e257–e267.
3. Adams, J.L., Smothers, J., Srinivasan, R., Hoos, A., Big opportunities for small molecules in immuno-oncology. Nat. Rev. Drug Discov. 14:9 (2015), 603–622.
4. Sierra, J.R., Cepero, V., Giordano, S., Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer, 9, 2010, 75.
5. Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J., Natural innate and adaptive immunity to cancer. Ann. Rev. Immunol. 29 (2011), 235–271.
6. Chanmee, T., Ontong, P., Konno, K., Itano, N., Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 6:3 (2014), 1670–1690.
7. Devaud, C., Westwood, J.A., Teng, M.W., John, L.B., Yong, C.S., Duong, C.P., Smyth, M.J., Darcy, P.K., Kershaw, M.H., Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors. Oncoimmunology, 3(11), 2014, e963395.
8. Yan, X., Wu, C., Chen, T., Santos, M.M., Liu, C.L., Yang, C., Zhang, L., Ren, J., Liao, S., Guo, H., Sukhova, G.K., Shi, G.P., Cathepsin S inhibition changes regulatory T-cell activity in regulating bladder cancer and immune cell proliferation and apoptosis. Mol. Immunol. 82 (2016), 66–74.
9. Chaudhary, B., Elkord, E., Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines, 4(3), 2016.
10. Ni, Y.H., Ding, L., Huang, X.F., Dong, Y.C., Hu, Q.G., Hou, Y.Y., Microlocalization of CD68+ tumor-associated macrophages in tumor stroma correlated with poor clinical outcomes in oral squamous cell carcinoma patients. Tumour Biol. 36:7 (2015), 5291–5298.
11. Liu, M., Luo, F., Ding, C., Albeituni, S., Hu, X., Ma, Y., Cai, Y., McNally, L., Sanders, M.A., Jain, D., Kloecker, G., Bousamra, M. 2nd, Zhang, H.G., Higashi, R.M., Lane, A.N., Fan, T.W., Yan, J., Dectin-1 Activation by a Natural Product beta-Glucan Converts Immunosuppressive Macrophages into an M1-like Phenotype. J. Immunol. 195:10 (2015), 5055–5065.
12. Caetano, M.S., Zhang, H., Cumpian, A.M., Gong, L., Unver, N., Ostrin, E.J., Daliri, S., Chang, S.H., Ochoa, C.E., Hanash, S., Behrens, C., Wistuba II, Sternberg, C., Kadara, H., Ferreira, C.G., Watowich, S.S., Moghaddam, S.J., IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras-Mutant lung cancer. Cancer Res. 76:11 (2016), 3189–3199.
13. Buchert, M., Burns, C.J., Ernst, M., Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 35:8 (2016), 939–951.
14. Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J.M., Schroeder, A., Sheehy, A., Buettner, R., Proia, D., Kowolik, C.M., Xin, H., Armstrong, B., Bebernitz, G., Weng, S., Wang, L., Ye, M., McEachern, K., Chen, H., Morosini, D., Bell, K., Alimzhanov, M., Ioannidis, S., McCoon, P., Cao, Z.A., Yu, H., Jove, R., Zinda, M., The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16:6 (2009), 487–497.
15. Yu, H., Lee, H., Herrmann, A., Buettner, R., Jove, R., Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14:11 (2014), 736–746.
16. Yu, H., Kortylewski, M., Pardoll, D., Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7:1 (2007), 41–51.
17. Zhang, G., Guo, L., Yang, C., Liu, Y., He, Y., Du, Y., Wang, W., Gao, F., A novel role of breast cancer-derived hyaluronan on inducement of M2-like tumor-associated macrophages formation. Oncoimmunology, 5(6), 2016, e1172154.
18. Lee, J.H., Kim, C., Baek, S.H., Ko, J.H., Lee, S.G., Yang, W.M., Um, J.Y., Sethi, G., Ahn, K.S., Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer. Oncotarget, 2016.
19. Che, S., Sun, T., Wang, J., Jiao, Y., Wang, C., Meng, Q., Qi, W., Yan, Z., miR-30 overexpression promotes glioma stem cells by regulating Jak/STAT3 signaling pathway. Tumour Biol. 36:9 (2015), 6805–6811.
20. Xie, C., Wu, L., Mei, H., Soloshonok, V.A., Han, J., Pan, Y., Generalized access to fluorinated beta-keto amino compounds through asymmetric additions of alpha, alpha-difluoroenolates to CF3-sulfinylimine. Org. Biomol. Chem. 12:39 (2014), 7836–7843.
21. Huang, Z., Yang, Y., Jiang, Y., Shao, J., Sun, X., Chen, J., Dong, L., Zhang, J., Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers. Biomaterials 34:3 (2013), 746–755.
22. Yamashita, M., Shinohara, T., Tsuji, S., Myrvik, Q.N., Nishiyama, A., Henriksen, R.A., Shibata, Y., Catalytically inactive cyclooxygenase 2 and absence of prostaglandin E2 biosynthesis in murine peritoneal macrophages following in vivo phagocytosis of heat-killed Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 179:10 (2007), 7072–7078.
23. Lin, X., Zheng, W., Liu, J., Zhang, Y., Qin, H., Wu, H., Xue, B., Lu, Y., Shen, P., Oxidative stress in malignant melanoma enhances tumor necrosis factor-alpha secretion of tumor-associated macrophages that promote cancer cell invasion. Antioxid. Redox Signal. 19:12 (2013), 1337–1355.
24. Pardanani, A., Hood, J., Lasho, T., Levine, R.L., Martin, M.B., Noronha, G., Finke, C., Mak, C.C., Mesa, R., Zhu, H., Soll, R., Gilliland, D.G., Tefferi, A., TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21:8 (2007), 1658–1668.
25. Takeda, K., Clausen, B.E., Kaisho, T., Tsujimura, T., Terada, N., Forster, I., Akira, S., Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:1 (1999), 39–49.
26. Li, L., Xu, T., Huang, C., Peng, Y., Li, J., NLRC5 mediates cytokine secretion in RAW264.7 macrophages and modulated by the JAK2/STAT3 pathway. Inflammation 37:3 (2014), 835–847.
27. Pallandre, J.R., Brillard, E., Crehange, G., Radlovic, A., Remy-Martin, J.P., Saas, P., Rohrlich, P.S., Pivot, X., Ling, X., Tiberghien, P., Borg, C., Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J. Immunol. 179:11 (2007), 7593–7604.
28. Ye, T.H., Yang, F.F., Zhu, Y.X., Li, Y.L., Lei, Q., Song, X.J., Xia, Y., Xiong, Y., Zhang, L.D., Wang, N.Y., Zhao, L.F., Gou, H.F., Xie, Y.M., Yang, S.Y., Yu, L.T., Yang, L., Wei, Y.Q., Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death Disease, 8(1), 2017, e2534.
29. Miklossy, G., Hilliard, T.S., Turkson, J., Therapeutic modulators of STAT signalling for human diseases. Nat. Rev. Drug Discov. 12:8 (2013), 611–629.
30. Schirlin, D., Baltzer, S., Altenburger, J.M., Tarnus, C., Remy, J.M., Difluoromethyleneketone retroamide, a versatile concept of inactivation of proteolytic enzymes. Tetrahedron 52:1 (1996), 305–318.
31. Silva, A.M., Cachau, R.E., Sham, H.L., Erickson, J.W., Inhibition and catalytic mechanism of HIV-1 aspartic protease. J. Mol. Biol. 255:2 (1996), 321–346.
32. Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., Gabrilovich, D., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172:1 (2004), 464–474.
33. Nefedova, Y., Cheng, P., Gilkes, D., Blaskovich, M., Beg, A.A., Sebti, S.M., Gabrilovich, D.I., Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J. Immunol. 175:7 (2005), 4338–4346.
34. Lu, P., Yu, B., Xu, J., Cucurbitacin B regulates immature myeloid cell differentiation and enhances antitumor immunity in patients with lung cancer. Cancer Biother. Radiopharm. 27:8 (2012), 495–503.
35. Liu, Y., Wang, Y.R., Ding, G.H., Yang, T.S., Yao, L., Hua, J., He, Z.G., Qian, M.P., JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway. OncoTargets Ther. 9 (2016), 4425–4433.
36. Mace, T.A., Bloomston, M., Lesinski, G.B., Pancreatic cancer-associated stellate cells: a viable target for reducing immunosuppression in the tumor microenvironment. Oncoimmunology, 2(7), 2013, e24891.
37. Ko, H.J., Kim, Y.J., Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer. Arch. Pharm. Res. 39:11 (2016), 1597–1608.
38. Kujawski, M., Zhang, C., Herrmann, A., Reckamp, K., Scuto, A., Jensen, M., Deng, J., Forman, S., Figlin, R., Yu, H., Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 70:23 (2010), 9599–9610.
39. Kim, M.J., Nam, H.J., Kim, H.P., Han, S.W., Im, S.A., Kim, T.Y., Oh, D.Y., Bang, Y.J., OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 335:1 (2013), 145–152.
40. Swiatek-Machado, K., Mieczkowski, J., Ellert-Miklaszewska, A., Swierk, P., Fokt, I., Szymanski, S., Skora, S., Szeja, W., Grynkiewicz, G., Lesyng, B., Priebe, W., Kaminska, B., Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biol. Ther. 13:8 (2012), 657–670.
41. Liu, L., Nam, S., Tian, Y., Yang, F., Wu, J., Wang, Y., Scuto, A., Polychronopoulos, P., Magiatis, P., Skaltsounis, L., Jove, R., 6-Bromoindirubin-3′-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res. 71:11 (2011), 3972–3979.
42. Rajappa, P., Cobb, W.S., Vartanian, E., Huang, Y., Daly, L., Hoffman, C., Zhang, J., Shen, B., Yanowitch, R., Garg, K., Cisse, B., Haddock, S., Huse, J.T., Pisapia, D.J., Chan, T.A., Lyden, D., Bromberg, J., Greenfield, J.P., Malignant astrocytic tumor progression potentiated by JAK-mediated recruitment of myeloid cells. Clin. Cancer Res., 2016.
43. Maenhout, S.K., Du Four, S., Corthals, J., Neyns, B., Thielemans, K., Aerts, J.L., AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. Oncotarget 5:16 (2014), 6801–6815.
44. Gritsina, G., Xiao, F., O'Brien, S.W., Gabbasov, R., Maglaty, M.A., Xu, R.H., Thapa, R.J., Zhou, Y., Nicolas, E., Litwin, S., Balachandran, S., Sigal, L.J., Huszar, D., Connolly, D.C., Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth. Mol. Cancer Ther. 14:4 (2015), 1035–1047.
45. Xin, H., Herrmann, A., Reckamp, K., Zhang, W., Pal, S., Hedvat, M., Zhang, C., Liang, W., Scuto, A., Weng, S., Morosini, D., Cao, Z.A., Zinda, M., Figlin, R., Huszar, D., Jove, R., Yu, H., Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 71:21 (2011), 6601–6610.